microLIQUID will be at Compamed 2017 this November 13-16 in Düseldorf, Germany.
We will be pleased to invite you to join Hall 8a/F34.1, where we will be demonstrating our latest offerings and technologies (services in mass manufacturing of microfluidic components and automated instruments for the IVD and pharma sector, for example.) and we will have our top product experts on hand to answer your questions.
Looking forward to seeing you.
microLIQUID will be at the 2017 AACC Clinical Lab Expo this August 1-3 in San Diego, CA.
AACC is a global scientific and medical professional organization dedicated to clinical laboratory science and its application to healthcare. Their leadership in education, advocacy and collaboration helps lab professionals adapt to change and do what they do best: provide vital insight and guidance so patients get the care they need.
On behalf of our company, if you are attending to AACC, we want to take advantage to have a meeting with you in order to talk about our common interests.
We will be pleased to invite you to join our booth #630, where we will be showcasing our latest offerings and technologies, and we will have our top product experts on hand to answer your questions.
Looking forward to seeing you.
Microfluidic Event in Germany
During three days in November, from 14 to 17 November, we have been part of the most important trade fair for In-Patient and out-patient Medicine in the city of Düsseldorf (Germany), MEDICA 2016.
Medica is the most attractive fair for the people who are working in the Health Care industry. There have been more than 130,000 visitors from over 120 countries, having the chance to take part in numerous special events, such as international conferences and forums.
Moreover Medica is the focus of the worldwide medical trade, and it has the largest and most comprehensive product display.
Microfluidics is a technology which has a big presence in the fair, as many of the solutions offered to the market in Diagnostics – IVD Market are based on it.
The trade fair we have been attending has more than 5.000 exhibitors from all around the world, with more than 19 halls on the exhibit area.
Furthermore, it is important to know that more than 500 of the exhibitors where from the United States of America and Canada.
Two members of our company have been attending the Medica world trade fair, having different meetings. As visitors, you are able to contact many companies in the Medical Device and Diagnostics in order to expand our business portfolio.
Microfluidic Event in the North of Spain
The 19th of October , BIOARABA – Conference on Research and Innovation(the 17th Conference on Research OSI UNIVERSITY HOSPITAL ARABA / BIOARABA Research Institute, in collaboration with the Campus of Álava of the UPV / EHU) was held in Vitoria / Gasteiz, more precisely in the Palacio Europa, aimed at people who work on investigation and people who are interested in the topic of BIOTECHNOLOGY.
It has been a seminar directed by professionals who work on investigation and the citizens, who take advantage of the investigations that the companies carry out.
That is why, the citizens have had a great importance in this seminar, letting them choose the principal topic of the event, creating a bridge between professional people and stakeholders that do not know much about the topic, but moreover, are interested on it.
The seminar had two important points. On one hand, there were conferences where professionals take part, which were organized in “Workshops” and everybody give their opinion and experience about the topic. We worked on “NEW ANALYTICAL TECHNOLOGIES IN HEALTH”, been expertly managed by Arantxa Goicolea from UPV/EHU.
On the other hand, and as mentioned before, the citizens take part on the annual investigation award ceremony and they are also able to take part in the meeting of “Healthy aging, a health social and technological perspective” where the experts shared their opinion and knowledge about the topic.
One of our team member took part in this workshop talking about “New analytical technologies in health” together with, for example, Carmen Zugaza (Osakidetza),Javier Garaizar (UPV/EHU), Lourdes Basabe(UPV(EHU), Alberto Gómez (UPV), Carolina Núñez Domingo (UPV) or Raúl Pérez González (I+Med) and Jesica Ruiz Pérez (I+Med). Some of the topics discussed where Clinical analysis, immunological diagnosis or microfluidic systems.
Microfluidic Application in the Neuro field
An innovative project with Hospital de Valdecilla(IDIVAL), together with microLIQUID and CSIC reaches the centre of the technology talent, the MIT in Boston.
A project lead by the Head of Clinical Neurophysiology and the attending physician of Intensive Care Medicine of HUMV and IDIVAL, has been one of the 15 international teams selected by MIT #Idea2Global program, developed by the prestigious Massachusetts Institute of Technology (MIT) in Boston (USA). The project has been developed in close collaboration with Instituto Cajal and Microliquid.
The selected teams have won 6 months of training and mentoring of their innovation projects with professors at MIT and other world-class institutions. The program will provide intensive training in innovation methods, development of collaborative projects and specific mentoring team. Moreover, it will provide the experience to help the projects to change from being a new idea to work in the real life.
WHICH IS THE PROJECT?
The idea of the project of great level of technology comes out from Valdecilla, and through the “Foundation for Innovation and Foresight in Health in Spain” (Fipse), which is a non-profit private entity on health research with the Ministry of health and pharmaceutical companies coverage, has gone to the Technology institute in Massachusetts (MIT) in Boston.
The aim of it is to prevent the supervening brain damage while a patient is in coma. And the way to achieve it is the creation of an innovative electrode capable of detecting phenomena which cause the death of neurons that exacerbate the initial injury.
More information at EL DIARIO MONTAÑES
Microfluidic Event in Spain
Microliquid has attended the “8th International meeting in Biotechnology “ from the 28th to the 30th of September, held in BEC (Bilbao). It is important to say that more than 850 companies went to the meeting and almost the 34% of the attending companies where international, coming from 28 different countries. Moreover, during these 3 days, there have been more than 3.300 meeting or partnerings, with more than 2.000 people of different companies taking part.
Biospain is a biennial event organized by ASEBIO, the Spanish association of Biotechnology Companies, in collaboration with other organizations, in this case, the Basque Business Development Agency. Due to the increasing international rivalry, this meeting is important for companies working in the Biotechnology field, in order to expand what they do and learn from other companies. BioSpain 2016 has had also a greater presence of USA companies and organizations, being USA the guest country in this eighth edition. People form the states of Maryland, Massachusetts, North Carolina, Pennsylvania, Texas, Virginia and Puerto Rico have attended the meeting. Moreover, this year the participation of national companies has raised, more specifically Galicia, Basque Country, Cataluña, Valencia or Baleares. Some of the topics discussed at BioSpain 2016 are oncology, Alzheimer, food, vaccine or new diagnostic methods.
Two of the members of our company have been in the meeting during the three days, trying to know more about other companies working in the same field of us, and moreover, letting them know what Microliquid does. Apart from having a stand to show what we do, Microliquid has been attending the Partnering area, where it was possible to talk to other companies, try to explain how our company works, listen to what they do, and sometimes, open new ways to work together, as a team, or helping each other.
Moreover, Microliquid makes a positive assessment of the fair, taking into account that a lot of people have attended our stand, new companies know about us, and we have been able to make new alliances with other companies.
To finish with, Ion Arocena, the director of the Spanish Association of Biotechnology Companies (Asebio), says that “We think that BioSpain 2016 has been a good representation of the sector worldwide” , and he makes a positive evaluation of those three days.
Microfluidic Event in Spain
Also the international approach with 34% of delegates attending from outside of Spain and fully business oriented. Is one of the largest Forum in the world with more than 850 companies coming and in one to one meetings, over 3.000 every edition.
The meeting will be in Bilbao, in the Bilbao Exhibition Center from the 28th to the 30th of September and here you can find the schedule/program: http://www.biospain2016.org/Program
microLIQUID will be there with one stand, within the Biobasque pavilion where we will show our latest developments and services. It is a great opportunity to meet and explain our capabilities for the market.
Options for collaboration/partnering:
For more information: [email protected]
Microfluidics in the Catalogue
MicroLIQUID integrated in the new BIOBASQUE Catalog, where all the information of the biotech companies of the Basque Region is available.
Here you can get the full information about the companies:
The BASQUE BIOCLUSTER is a non-profit association constituted in 2010, and represents the idea of enhancing the biosciences sector in the Basque Country. The coordination, the collaboration with all the stakeholders in the sphere of biosciences, promoting business cooperation is the basis for the competitive development of its companies and their internationalisation, and is greatly contributing to the development and positioning of the Basque bio sector.
Today the Basque Biocluster has 30 partner businesses, 58 including their subsidiaries, which in 2014 had a turnover of €268 million, 78.7% (€211 million) of which came from the export of their products and services to international markets. As a whole, the companies in the association contribute to the maintenance of 1,632 jobs.
Industry based on biosciences is characterised by the close relationship between research, innovation and competitiveness, and largely rests on the appearance of a new type of companies whose objective is to exploit advanced technologies related to the sciences of life, in order to respond to myriad needs in various industrial spheres.
In today’s catalog, more than 80 entities are dedicated to biotechnology research, of which 51 had biotechnology as their main or exclusive activity, assigning more than half of their internal expenses to biotechnology R&D. Of these 80 entities, 70 are biotechnology companies.
The bio sector employs 1,183 people full time, or in other words, 6.4% of total R&D personnel in the Basque Country, with the outstanding presence of women, who represent more than 60% of all people working full time in biotechnology.
Research personnel, for their part, stand at 903 people, 76% of the total.
Technology Platforms like this, are a group of stakeholders in a particular sector, led by industry, with the aim of defining a Strategic Research Agenda (acronym: SRA) on important issues and great social relevance, in which achieve European objectives of growth, competitiveness and sustainability depend on technological advances and research in the medium and long term.
Technology Platforms are based on the definition of a Strategic Research Agenda and mobilizing the critical mass of research and innovation effort needed.
Guide research in supply to industrial interests and the interests of society. The aim of this platform is to reach a consensus among all (companies and researchers) on issues of interest to be investigated. This consensus will materialize in the development of a Strategic Research Agenda.
The intention is that projects to be submitted to the various national R & D + Innovation plans are made based on the needs of the sector and not just those of the research centers or other stakeholders only.
microLIQUID joins in the project based on the capacity of the company of generating new detection systems in the Food & Health sector, like the example we see in the picture
On February 26 was made official the agreement that the two companies have signed for the distribution of the neuronal microprobes Fprobes for research in EPILEPSY, PARKINSON and other BRAIN DISEASES. Cibertec will be the exclusive dealer entitled to sell the product in the Spanish national market.
Cibertec is the Spanish leader in production and distributor of devices and equipment for research and teaching in neurology and in several other fields. The company was constituted in 1977 and was born as a manufacturer of a limited number of equipment, range of stimulators and electrophysiology window discriminator, but with an advanced design.
Over the years Cibertec have been manufacturing a wide range of new equipment, mostly under specifications of its customers, and at the same time marketing products manufactured by prestigious companies.
The new distribution agreement allows Cibertec to sell the fProbes and the fPack, and also the developments coming soon in the Neuro field by microLIQUID.
The fProbes are probes with integrated electrophysiological recording and the simultaneous release of drugs in the brain with ,currently, experimental purposes. For proper functionality, fProbes are integrated in a package, the fPack, which ensures the electrical and fluidic connection.
This technology has been developed as a result of scientific collaboration between the Cajal Institute CSIC, the IKERLAN Technology Centre and the
University of Zaragoza
Here you can find the link where all is explain in deep:
Both companies have started to work the Beta Tester Program for a better landing in the market. This beta program is simply the starting point, offering to researchers a pack of one encapsulate and 5 units of the probes, in order to test the product.
Microliquid has found a perfect strategic partner to output its own product and at the same time Cibertec complete its product portfolio with a unique product in the market.
The advantages of this agreement are clear and the complementary fields of both companies allow developing the market together.